Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513753-75-00

Acronym

BLCL-AMC-03

Enrollment

Registered

2024-07-11

Start date

2024-08-12

Completion date

2024-09-17

Last updated

2024-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No medical condition.

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Portugal

None listed

Source: EU CTIS · Data processed: Feb 4, 2026